GSK Is Maintained at Buy by Jefferies
GSK Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on GSK, Raises Price Target to $53
Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.
GSK Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove
Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer
Jefferies Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Raises Target Price to $53
Jefferies analyst Peter Welford maintains $GlaxoSmithKline(GSK.US)$ with a buy rating, and adjusts the target price from $28.48 to $53.According to TipRanks data, the analyst has a success rate of 52.
Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for over 70,000 lawsuits alleging that the heartburn drug Zantac causes
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Express News | GSK : Jefferies Raises Target Price to $53 From $52.5
Unusual Options Activity: CTLT, STX and Others Attract Market Bets, CTLT V/OI Ratio Reaches 250.0
EST Jul 1st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Bird Flu Vaccine Faces Hurdles Without Better Data, Critics Say
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK Settles Zantac Litigation in Illinois, US
GSK (GSK.L) entered a confidential settlement with Martin Gross, who filed a case against the company's heartburn medication ranitidine, marketed as Zantac, in the Illinois state court in the US. The
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
GSK Reaches Confidential Settlement in Illinois Zantac Litigation
GSK (GSK) Price: 38.92, Change: +0.27, Percent Change: +0.71
GSK Issues Statement Regarding The Zantac (Ranitidine) Litigation; Has Reached A Confidential Settlement With Martin Gross; GSK Does Not Admit Any Liability In This Settlement
GSK Issues Statement Regarding The Zantac (Ranitidine) Litigation; Has Reached A Confidential Settlement With Martin Gross; GSK Does Not Admit Any Liability In This Settlement
GSK: Case Is Related to Ranitidine Litigation
GSK: Case Is Related to Ranitidine Litigation
GSK Will Continue to Vigorously Defend Itself, Manage Litigation in Best Interests of Group, Shareholders
GSK Will Continue to Vigorously Defend Itself, Manage Litigation in Best Interests of Group, Shareholders
Statement: Zantac (Ranitidine) Litigation – Gross Case
GSK plc (LSE/NYSE: GSK) has reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will